Syndax Pharmaceuticals Reports Positive Data From Leukemia Combo Drug Trial

MT Newswires Live06-11 20:17

Syndax Pharmaceuticals (SNDX) said Thursday that an experimental combination treatment achieved a composite complete remission rate of 71% in patients with certain forms of relapsed or treatment-resistant acute myeloid leukemia in a phase 1/2 trial.

The company said the treatment, which combines Revuforj, decitabine/cedazuridine and venetoclax, produced an overall response rate of 88% among 42 patients whose disease had returned or failed to respond to previous treatments.

About 45% of patients went on to receive a stem cell transplant after treatment, the company added.

After a median follow-up of 22 months, patients who achieved remission remained in response for a median of 10.5 months, the company said.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2642049281?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-11 20:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2642049281","market":"sg","top_or_hot":-1,"title":"Syndax Pharmaceuticals Reports Positive Data From Leukemia Combo Drug Trial","media":"MT Newswires Live","content":"<html><body><p> Syndax Pharmaceuticals (SNDX) said Thursday that an experimental combination treatment achieved a composite complete remission rate of 71% in patients with certain forms of relapsed or treatment-resistant acute myeloid leukemia in a phase 1/2 trial.</p><p>The company said the treatment, which combines Revuforj, decitabine/cedazuridine and venetoclax, produced an overall response rate of 88% among 42 patients whose disease had returned or failed to respond to previous treatments.</p><p>About 45% of patients went on to receive a stem cell transplant after treatment, the company added.</p><p>After a median follow-up of 22 months, patients who achieved remission remained in response for a median of 10.5 months, the company said.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Syndax Pharmaceuticals Reports Positive Data From Leukemia Combo Drug Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSyndax Pharmaceuticals Reports Positive Data From Leukemia Combo Drug Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-11 20:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Syndax Pharmaceuticals (SNDX) said Thursday that an experimental combination treatment achieved a composite complete remission rate of 71% in patients with certain forms of relapsed or treatment-resistant acute myeloid leukemia in a phase 1/2 trial.</p><p>The company said the treatment, which combines Revuforj, decitabine/cedazuridine and venetoclax, produced an overall response rate of 88% among 42 patients whose disease had returned or failed to respond to previous treatments.</p><p>About 45% of patients went on to receive a stem cell transplant after treatment, the company added.</p><p>After a median follow-up of 22 months, patients who achieved remission remained in response for a median of 10.5 months, the company said.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2642049281","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2642049281","pubTimestamp":1781180248,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Syndax Pharmaceuticals (SNDX) said Thursday that an experimental combination treatment achieved a composite complete remission rate of 71% in patients with certain forms of relapsed or treatment-resis","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","SNDX":"Syndax Pharmaceuticals, Inc. "},"translate_title":"Syndax制药公司报告白血病组合药物试验的积极数据","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNDX":1.5},"content_text":"Syndax Pharmaceuticals (SNDX) said Thursday that an experimental combination treatment achieved a composite complete remission rate of 71% in patients with certain forms of relapsed or treatment-resistant acute myeloid leukemia in a phase 1/2 trial.The company said the treatment, which combines Revuforj, decitabine/cedazuridine and venetoclax, produced an overall response rate of 88% among 42 patients whose disease had returned or failed to respond to previous treatments.About 45% of patients went on to receive a stem cell transplant after treatment, the company added.After a median follow-up of 22 months, patients who achieved remission remained in response for a median of 10.5 months, the company said.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2642049281","isCrawlerRequest":true}